{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:16:07Z","timestamp":1791083767694,"version":"4.1.0"},"publisher-location":"Cham","reference-count":78,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030999940","type":"print"},{"value":"9783030999957","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/164_2021_560","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:49:48Z","timestamp":1642153788000},"page":"387-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Drugs for Treating Obesity"],"prefix":"10.1007","author":[{"given":"Donna H.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"2","key":"560_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT et al (2012) Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20(2):330\u2013342","journal-title":"Obesity (Silver Spring)"},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/oby.2002.86","volume":"10","author":"JW Anderson","year":"2002","unstructured":"Anderson JW, Greenway FL, Fujioka K et al (2002) Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10:633\u2013641","journal-title":"Obes Res"},{"key":"560_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne LA, Rubino D, for the COR-II Study Group et al (2013) A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity related risk factors (COR-II). Obesity 21:935\u2013943","journal-title":"Obesity"},{"issue":"7","key":"560_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1210\/jc.2018-00258","volume":"103","author":"KL Ayers","year":"2018","unstructured":"Ayers KL, Glicksberg BS, Garfield AS, Longerich S et al (2018) Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab 103(7):2601\u20132612","journal-title":"J Clin Endocrinol Metab"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","volume":"397","author":"S Becerril","year":"2021","unstructured":"Becerril S, Fr\u00fchbeck G (2021) Cagrilintide plus semaglutide for obesity management. Lancet 397:1687\u20131689","journal-title":"Lancet"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G et al (2016) Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 40:1310\u20131319","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"560_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.ijo.0801645","volume":"2","author":"H Cavaliere","year":"2001","unstructured":"Cavaliere H, Floriano I, Medeiros-Neto G (2001) Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes (Lond) 2(7):1095\u20131099","journal-title":"Int J Obes (Lond)"},{"issue":"23","key":"560_CR9","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"JP Chanoine","year":"2005","unstructured":"Chanoine JP, Hampl S, Jensen C et al (2005) Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293(23):2873\u20132883","journal-title":"JAMA"},{"key":"560_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41591-018-0015-9","volume":"24","author":"K Cl\u00e9ment","year":"2018","unstructured":"Cl\u00e9ment K, Biebermann H, Farooqi IS et al (2018) MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med 24:551\u2013555","journal-title":"Nat Med"},{"issue":"12","key":"560_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","volume":"8","author":"K Cl\u00e9ment","year":"2020","unstructured":"Cl\u00e9ment K, van den Akker E, Argente J et al (2020) Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 8(12):960\u2013970","journal-title":"Lancet Diabetes Endocrinol"},{"key":"560_CR12","unstructured":"ClinicalTrial.gov. A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04184622. Accessed 28 Mar 2021"},{"issue":"10","key":"560_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.molmet.2017.06.015","volume":"6","author":"TH Collet","year":"2017","unstructured":"Collet TH, Dubern B, Mokrosinski J et al (2017) Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab 6(10):1321\u20131329","journal-title":"Mol Metab"},{"issue":"17","key":"560_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMp1211277","volume":"367","author":"E Colman","year":"2012","unstructured":"Colman E, Golden J, Roberts M et al (2012) The FDA\u2019s assessment of two drugs for chronic weight management. N Engl J Med 367(17):1577\u20131579","journal-title":"N Engl J Med"},{"key":"560_CR15","unstructured":"Contrave Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/200063s000lbl.pdf. Accessed 30 June 2021"},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314:687\u2013699","journal-title":"JAMA"},{"key":"560_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Kleist Jeppesen O et al (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397:971\u2013984","journal-title":"Lancet"},{"issue":"10286","key":"560_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelson KK, Kankam M et al (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397(10286):1736\u20131748","journal-title":"Lancet"},{"issue":"1","key":"560_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","volume":"31","author":"TD Filippatos","year":"2008","unstructured":"Filippatos TD, Derdemezis CS, Gazi IF et al (2008) Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 31(1):53\u201365","journal-title":"Drug Saf"},{"issue":"3","key":"560_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/jpet.121.000567","volume":"377","author":"MM Fletcher","year":"2021","unstructured":"Fletcher MM, Keov P, Truong TT et al (2021) AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison to six selective and non-selective agonists. J Pharmacol Exp Ther 377(3):417\u2013440","journal-title":"J Pharmacol Exp Ther"},{"issue":"10160","key":"560_CR21","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2008","unstructured":"Frias JP, Nauck MA, Van J et al (2008) Efficacy and safety of LY3298176, a novel dual gip and glp-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180\u20132193","journal-title":"Lancet"},{"issue":"3","key":"560_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S et al (2021) The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 23(3):754\u2013762","journal-title":"Diabetes Obes Metab"},{"issue":"9774","key":"560_CR23","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH et al (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 377(9774):1341\u20131352","journal-title":"Lancet"},{"issue":"2","key":"560_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M et al (2012) Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95(2):297\u2013308","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"560_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M et al (2009) Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17(1):30\u201339","journal-title":"Obesity (Silver Spring)"},{"issue":"9741","key":"560_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA et al (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 376(9741):595\u2013605","journal-title":"Lancet"},{"issue":"Suppl 3","key":"560_CR27","first-page":"S12","volume":"21","author":"R Guerciolini","year":"1997","unstructured":"Guerciolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21(Suppl 3):S12\u2013S23","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"11","key":"560_CR28","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/dom.14133","volume":"22","author":"R Haws","year":"2020","unstructured":"Haws R, Brady S, Davis E et al (2020) Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab 22(11):2133\u20132140","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"560_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/obr.12143","volume":"15","author":"SB Heymsfield","year":"2014","unstructured":"Heymsfield SB, Gonzalez MC, Shen W et al (2014) Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev 15(4):310\u2013321","journal-title":"Obes Rev"},{"issue":"1","key":"560_CR30","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R et al (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open 4(1):e2033457","journal-title":"JAMA Netw Open"},{"key":"560_CR31","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, for the COR-Diabetes Study Group et al (2013) Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36:4022\u20134029","journal-title":"Diabetes Care"},{"issue":"4","key":"560_CR32","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409\u20131439","journal-title":"Physiol Rev"},{"issue":"2","key":"560_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.15171\/jnp.2016.14","volume":"5","author":"Y Humayun","year":"2016","unstructured":"Humayun Y, Ball KC, Lewin JR et al (2016) Acute oxalate nephropathy associated with orlistat. J Nephropathol 5(2):79\u201383","journal-title":"J Nephropathol"},{"key":"560_CR34","unstructured":"Imcivree\u2122 Price. https:\/\/www.bioworld.com\/articles\/500740-rhythm-wins-first-fda-approval-for-obesity-drug-imcivree?v=preview. Accessed 30 June 2021"},{"key":"560_CR35","unstructured":"Imcivree\u2122 Product Label, EMA. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/imcivree. Accessed 30 June 2021"},{"key":"560_CR36","unstructured":"Imcivree\u2122 Product Label, FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213793s000lbl.pdf. Accessed 30 June 2021"},{"key":"560_CR37","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/jbmr.3214","volume":"32","author":"KC Johnson","year":"2017","unstructured":"Johnson KC, Bray GA, Cheskin LJ, Look AHEAD Study Group et al (2017) The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial. J Bone Miner Res 32:2278\u20132287","journal-title":"J Bone Miner Res"},{"key":"560_CR38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2337\/db12-0598","volume":"62","author":"P Kievit","year":"2013","unstructured":"Kievit P, Halem H, Marks DL et al (2013) Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62:490\u2013497","journal-title":"Diabetes"},{"key":"560_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/oby.2001.13","volume":"9","author":"RL Kolotkin","year":"2001","unstructured":"Kolotkin RL, Crosby RD, Kosloski KD, Williams GR (2001) Development of a brief measure to assess quality of life in obesity. Obes Res 9:102\u2013111","journal-title":"Obes Res"},{"key":"560_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/NEJMoa1512693","volume":"375","author":"P K\u00fchnen","year":"2016","unstructured":"K\u00fchnen P, Clement K, Wiegand S et al (2016) Proopiomelanocortin deficiency treated with a melanocortin-4receptor agonist. N Engl J Med 375:240\u2013246","journal-title":"N Engl J Med"},{"issue":"6","key":"560_CR41","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M et al (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring) 28(6):1050\u20131061","journal-title":"Obesity (Silver Spring)"},{"key":"560_CR42","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/oby.23079","volume":"29","author":"MR Laughlin","year":"2021","unstructured":"Laughlin MR, Osganian SK, Yanovski SZ, Lynch CJ (2021) Physiology of the weight-reduced state: a report from a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Obesity 29:S5\u2013S8","journal-title":"Obesity"},{"issue":"10077","key":"560_CR43","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW Le Roux","year":"2016","unstructured":"Le Roux CW, Astrup A, Fujioka K, for the show SCALE Obesity Prediabetes NN8022-1839 Study Group et al (2016) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet 389(10077):1399\u20131409","journal-title":"Lancet"},{"issue":"10120","key":"560_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391(10120):541\u2013551","journal-title":"Lancet"},{"issue":"5","key":"560_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 7(5):344\u2013355","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"560_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.7326\/0003-4819-155-7-201110040-00006","volume":"155","author":"ES Leblanc","year":"2011","unstructured":"Leblanc ES, O\u2019Connor E, Whitlock EP, Patnode CD, Kapka T (2011) Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 155(7):434\u2013447","journal-title":"Ann Intern Med"},{"key":"560_CR47","unstructured":"Lilly News Release. Investor.lilly.com\/news-releases\/news-release-details\/tirzepatide-achieved-superior-a1c-and-body-weight-reductions. Accessed 30 June 2021"},{"key":"560_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/oby.2006.84","volume":"14","author":"Look AHEAD Research Group","year":"2006","unstructured":"Look AHEAD Research Group (2006) The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 14:737\u2013752","journal-title":"Obesity"},{"issue":"Suppl 2","key":"560_CR49","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1002\/oby.22154","volume":"26","author":"PS MacLean","year":"2018","unstructured":"MacLean PS, Rothman AJ, Nicastro HL et al (2018) The accumulating data to optimally predict obesity treatment (ADOPT) core measures project: rationale and approach. Obesity (Silver Spring) 26(Suppl 2):S6\u2013S15","journal-title":"Obesity (Silver Spring)"},{"key":"560_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J et al (2016) Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 23:1\u201311","journal-title":"Cell Metab"},{"key":"560_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"issue":"7","key":"560_CR52","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1592\/phco.22.11.814.33627","volume":"22","author":"JR McDuffie","year":"2002","unstructured":"McDuffie JR, Calis KA, Booth SL et al (2002) Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 22(7):814\u2013822","journal-title":"Pharmacotherapy"},{"issue":"1","key":"560_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","volume":"12","author":"T Min","year":"2021","unstructured":"Min T, Bain SC (2021) The role of tirzepatide, dual gip and glp-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther 12(1):143\u2013157","journal-title":"Diabetes Ther"},{"key":"560_CR54","unstructured":"Mysimba Product Label. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mysimba-epar-product-information_en.pdf Accessed 30 June 2021"},{"issue":"10","key":"560_CR55","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L et al (2016) Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 315(10):990\u20131004","journal-title":"JAMA"},{"key":"560_CR56","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.ijo.0803631","volume":"31","author":"R Padwal","year":"2007","unstructured":"Padwal R, Kezouh A, Levine M, Etminan M (2007) Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 31:1567\u20131570","journal-title":"Int J Obes (Lond)"},{"key":"560_CR57","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.2147\/DMSO.S229802","volume":"12","author":"S Pearson","year":"2019","unstructured":"Pearson S, Kietsiriroje N, Ajjan RA (2019) Oral semaglutide in the management of type 2 diabetes: a report on the evidence to date. Diabetes Metab Syndr Obes 12:2515\u20132529","journal-title":"Diabetes Metab Syndr Obes"},{"key":"560_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","volume":"92","author":"E Pilitsi","year":"2019","unstructured":"Pilitsi E, Farr OM, Polyzos SA et al (2019) Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism 92:170\u2013192","journal-title":"Metabolism"},{"issue":"1","key":"560_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. SCALE obesity and prediabetes NN8022-1839 Study Group. N Engl J Med 373(1):11\u201322","journal-title":"N Engl J Med"},{"key":"560_CR60","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/oby.21005","volume":"23","author":"HJ Pownall","year":"2015","unstructured":"Pownall HJ, Bray GA, Wagenknecht LE, Look AHEAD Research Group et al (2015) Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 23:565\u2013572","journal-title":"Obesity (Silver Spring)"},{"key":"560_CR61","unstructured":"Qsivia Assessment Report (2013). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/qsiva-epar-public-assessment-report_en.pdf. Accessed 30 June 2021"},{"key":"560_CR62","unstructured":"Qsymia\u2122 Product Label, FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022580s000lbl.pdf. Accessed 30 June 2021"},{"issue":"1","key":"560_CR63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13543784.2020.1705277","volume":"29","author":"CJ Rebello","year":"2020","unstructured":"Rebello CJ, Greenway FL (2020) Obesity medications in development. Expert Opin Investig Drugs 29(1):63\u201371","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"560_CR64","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcsm.12205","volume":"8","author":"DS Rooks","year":"2017","unstructured":"Rooks DS, Laurent D, Praestgaard J et al (2017) Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle 8(5):727\u2013734","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"14","key":"560_CR65","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, STEP 4 Investigators et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414\u20131425","journal-title":"JAMA"},{"issue":"6","key":"560_CR66","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/oby.21107","volume":"23","author":"D Ryan","year":"2015","unstructured":"Ryan D, Acosta A (2015) GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) 23(6):1119\u20131129","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"560_CR67","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR (2017) Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep 6(2):187\u2013194","journal-title":"Curr Obes Rep"},{"key":"560_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM et al (2020) Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 229:61\u201369","journal-title":"Am Heart J"},{"key":"560_CR69","unstructured":"Saxenda\u2122 Product Label (EMA). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saxenda-epar-product-information_en.pdf. Accessed 30 June 2021"},{"key":"560_CR70","unstructured":"Saxenda\u2122 Product Label (FDA). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321Orig1s000lbl.pdf. Accessed 30 June 2021"},{"key":"560_CR71","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jbmr.1483","volume":"27","author":"AV Schwartz","year":"2012","unstructured":"Schwartz AV, Johnson KC, Kahn SE, Look AHEAD Research Group et al (2012) Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res 27:619\u2013627","journal-title":"J Bone Miner Res"},{"issue":"10","key":"560_CR72","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.3390\/molecules24101892","volume":"24","author":"S Sharma","year":"2019","unstructured":"Sharma S, Garfield AS, Shah B et al (2019) Current mechanistic and pharmacodynamic understanding of melanocortin-4 receptor activation. Molecules 24(10):1892","journal-title":"Molecules"},{"issue":"2","key":"560_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","volume":"7","author":"G Srivastava","year":"2018","unstructured":"Srivastava G, Apovian C (2018) Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep 7(2):147\u2013161","journal-title":"Curr Obes Rep"},{"issue":"1","key":"560_CR75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"J Torgerson","year":"2004","unstructured":"Torgerson J, Hauptman J, Boldrin M, Sj\u00f6str\u00f6m L (2004) Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155\u2013161","journal-title":"Diabetes Care"},{"issue":"1","key":"560_CR76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD et al (2011) Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 19(1):110\u2013120","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"560_CR77","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 37(11):1443\u20131451","journal-title":"Int J Obes (Lond)"},{"issue":"14","key":"560_CR78","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, STEP 3 Investigators et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14):1403\u20131413","journal-title":"JAMA"},{"key":"560_CR80","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, STEP 1 Study Group et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002","journal-title":"N Engl J Med"},{"issue":"8","key":"560_CR81","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/oby.23158","volume":"29","author":"RR Wing","year":"2021","unstructured":"Wing RR, Look AHEAD Research Group (2021) Does lifestyle intervention improve health of adults with overweight\/obesity and type 2 diabetes: findings from the Look AHEAD randomized trial. Obesity (Silver Spring) 29(8):1246\u20131258","journal-title":"Obesity (Silver Spring)"}],"container-title":["Handbook of Experimental Pharmacology","From Obesity to Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2021_560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T11:07:19Z","timestamp":1675940839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2021_560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030999940","9783030999957"],"references-count":78,"URL":"https:\/\/doi.org\/10.1007\/164_2021_560","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"17 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}